Compelling Value of Non-viral Genetic Modification

B-MoGen Non-viral Platform

B-MoGen’s more potent non-viral solutions enable therapeutic companies to have lower cost, safer products and supply chain stability.


Viral Gene Editing Nonviral Gene Editing
Virus Based Non-viral Based
Cost $35K – $45K per patient $8K – $12K per patient
Consistency Lot-to-lot variability
Supply shortages
Scalable and repeatable
Capacity Limited size of cargo
>Max 9kb
Can handle multiple CARs & TCRs with killer switch
Potency 10% of Tscm cells Above 60% of Tscm cells

Non-Viral Gene Therapy B-Mogen